REGN Earnings
Latest Revenue4.3B
Latest Net Income1.3B
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $12.62 | 4.3B | 1.3B | +16.7% | -4.7% |
| Q1 2026 | $6.99 | 3.6B | 727.2M | +19.0% | -7.8% |
| Q4 2025 | $8.20 | 3.9B | 844.6M | +2.5% | -3.9% |
| Q3 2025 | $14.09 | 3.8B | 1.5B | +0.9% | +13.6% |
| Q2 2025 | $13.24 | 3.7B | 1.4B | +3.6% | -0.1% |
| Q1 2025 | $7.58 | 3.0B | 808.7M | -3.7% | +13.1% |
| Q4 2024 | $8.53 | 3.8B | 917.7M | +10.3% | -21.7% |
| Q3 2024 | $12.40 | 3.7B | 1.3B | +10.6% | +30.8% |
| Q2 2024 | $13.25 | 3.5B | 1.4B | — | — |
| Q1 2024 | $6.70 | 3.1B | 722.0M | — | — |
| Q4 2023 | $10.90 | 3.4B | 1.2B | — | — |
| Q3 2023 | $9.48 | 3.4B | 1.0B | — | — |
Regeneron Pharmaceuticals (REGN) — Earnings